Atherosclerotic Renovascular Disease: Where to After ASTRAL and CORAL? - European Medical Journal

Atherosclerotic Renovascular Disease: Where to After ASTRAL and CORAL?


This webinar will discuss the epidemiology and management of atherosclerotic renovascular disease, with a focus on renal revascularisation. Clinical cases and randomised controlled trial evidence will be used to explore the indications and important considerations involved in revascularisation decision-making.

Topics explored in this webinar include:

  • the main findings and conclusions from the ASTRAL and CORAL trials;
  • revascularisation for high-risk cases;
  • the role of multidisciplinary team meetings in case selection; and
  • a consensus for intervention.


Philip Kalra, Professor of Nephrology at Salford Royal Hospital, Manchester, UK, and the University of Manchester, UK, graduated from Cambridge University, UK, and St Thomas’s Hospital Medical School, London, UK. He is Director of Research and Innovation in the Northern Care Alliance, the trust encompassing Salford Royal, where he has worked as Consultant Nephrologist since 1995. He was Academic Vice President of the UK Renal Association 2016–19, and Chair of the UK Kidney Research Consortium (UKKRC) during this time. He has been involved in the development of several large UK clinical trials in nephrology and cardiology, including the ASTRAL, PIVOTAL, and IRONMAN trials, and the NURTuRE cohort. He has played a role in improving collaboration between nephrology and cardiology in both scientific and educational endeavours.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now